Latest Hepatitis C/co-infection with HIV Stories
SAN DIEGO, April 15, 2011 /PRNewswire/ -- Aethlon Medical, Inc.
BALTIMORE, April 11, 2011 /PRNewswire/ -- Adherence to interferon, an important medication used to treat Hepatitis C, is critical to successfully clearing the virus that causes the disease. A new observational analysis by Medco Health Solutions, Inc.
A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis.
Early data from phase I trials of an HCV vaccine show encouraging results, with high immunogenicity and good safety profile.
Higher virologic response rates achieved at 4 weeks (RVR)* and maintained through 12 weeks of treatment (cEVR)** across all genotypes studied Princeton, NJ (PRWEB) April 2, 2011 â€“ Bristol-Myers Squibb Company (NYSE: BMY) today announced results from the Phase IIb EMERGE clinical trial, in which treatment with the investigational compound PEG-Interferon lambda and ribavirin achieved higher rates of rapid virologic response (RVR) in genotypes 1, 2, 3, and 4, and complete early...
Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple therapy in chronic hepatitis C (HCV) patients suppressed the emergence of resistant variants and resulted in a 100% rate of sustained virological response - undetectable HCV RNA - 12 weeks after treatment (SVR12).
Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus (HCV) must be prescribed and monitored by experts and specialists to ensure resistance is minimized.
RIDGEFIELD, Conn., April 2, 2011 /PRNewswire/ -- Boehringer Ingelheim today announced a preview of the study designs for the pivotal Phase 3 clinical trials evaluating BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus (HCV), the most challenging genotype to treat.
Early data from phase I trials of an HCV vaccine presented today at the International Liver CongressTM show encouraging results, with high immunogenicity and good safety profile.
Highly anticipated data from a number of clinical trials presented for the first time at the International Liver CongressTM confirmed that a range of new proteases inhibitors will help treat patients who have previously failed therapy for the treatment of chronic hepatitis C.
Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...
- A small wooded valley; a dell.
- The protecting weather-shed built around the entrance to a house.